Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Pyrotinib PK in Healthy Subjects
NCT04479891Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2019
- Primary completion
- Oct 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration at Day 9 and Area Under the Curve at Day 9. Started Sep 2019; status: completed.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04479891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04479891.